STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection

Medical University of Warsaw

Status: Not yet enrolling

Conditions: Vancomycin; Comparative Effectiveness of CDI Treatments; Fidaxomicin; Fecal Microbiota Transplantation (FMT); Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence

Treatments: Drug: Vancomycin (VAN) treatment; Drug: Fidaxomicin; Other: FMT (fecal microbiota transplantation)

Study type: Interventional

Funder types: Other

Identifiers

NCT07120490

2022/ABM/03/00047 (Other Grant/Funding Number)

STOP-CDI

Details and patient eligibility

About

The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care vancomycin in preventing recurrence of Clostridioides difficile infection (CDI) in high-risk adult patients.

CDI is a common healthcare-associated infection with rising incidence and high recurrence rates, particularly in elderly and immunocompromised individuals. While current guidelines recommend fidaxomicin as first-line therapy, its availability and reimbursement remain limited in some healthcare systems. FMT, although effective, is not widely implemented as first-line treatment. This study addresses the need for comparative, real-world data to inform treatment decisions for patients at high risk of severe or recurrent CDI.

Eligible participants include adults aged ≥65 years or younger patients with specific risk factors such as multiple comorbidities, prior CDI episodes, recent hospitalization, use of non-CDI antibiotics, or PPI therapy. Participants will be randomized in a 2:1:1 ratio to one of three treatment arms: (1) vancomycin plus FMT, (2) fidaxomicin, or (3) vancomycin alone. FMT is administered via capsules or, if necessary, alternative endoscopic routes.

The primary endpoint is CDI recurrence within 12 weeks following the initial treatment. Secondary endpoints include clinical cure, safety, and global cure. Exploratory analyses will assess microbiome changes and potential genomic predictors of response. A total of 424 participants will be enrolled across 10 clinical sites in Poland.

The study aims to provide robust, comparative evidence to support clinical guidelines and improve outcomes for patients with CDI, particularly in healthcare systems with limited access to novel therapies.

Full description

Clostridioides difficile infection (CDI) represents a persistent and growing challenge in modern healthcare, particularly among elderly, hospitalized, and immunocompromised patients. Despite the existence of evidence-based therapeutic guidelines, recurrence rates remain unacceptably high, often leading to cycles of reinfection and retreatment. These recurrent episodes are associated with increased morbidity, reduced quality of life, higher healthcare costs, and, in some cases, life-threatening complications.

While therapies such as fidaxomicin and fecal microbiota transplantation (FMT) have demonstrated superior efficacy in reducing recurrence compared to traditional vancomycin, access to these interventions remains inconsistent. Fidaxomicin is often restricted due to its high cost and limited reimbursement, while FMT-though highly effective-is not yet widely integrated into early-line treatment pathways, largely due to regulatory and logistical barriers, including donor screening, manufacturing infrastructure, and clinician training.

The STOP-CDI study is a multicenter, randomized, open-label, three-arm research experiment designed to directly compare the effectiveness of three therapeutic strategies in preventing recurrent CDI (rCDI) in a real-world, high-risk adult population. The project addresses key gaps identified by international societies such as ESCMID, which emphasize the need for high-quality, head-to-head comparative research in CDI management.

The primary objective is to determine which of the following approaches most effectively prevents CDI recurrence within 12 weeks after treatment completion:

1. Short-course oral vancomycin followed by FMT
2. Fidaxomicin monotherapy
3. Standard-of-care oral vancomycin

Participants will be randomized in a 2:1:1 allocation ratio, favoring the vancomycin plus FMT group to enable robust analysis of this relatively underutilized intervention. FMT is administered either as oral capsules containing freeze-dried donor microbiota or, when oral intake is not possible, through endoscopic routes such as colonoscopy or nasoenteric tubes. All FMT materials are sourced from rigorously screened donors under standardized laboratory protocols.

The study population includes 424 adult participants across 10 clinical sites in Poland, with recruitment targeting:

Adults aged 65 years or older, or

Younger adults with clearly defined risk factors for severe or recurrent CDI, such as:

• Multiple comorbidities (e.g., diabetes, malignancy, chronic kidney disease),
• Prior CDI episodes,
• Recent hospitalization,
• Use of non-CDI antibiotics,
• Ongoing proton pump inhibitor (PPI) therapy,
• Immunosuppressive treatment.

The primary endpoint of the experiment is CDI recurrence within 12 weeks following treatment, defined by return of symptoms (e.g., diarrhea) and laboratory confirmation of C. difficile toxin. Secondary endpoints include:

1. Initial clinical cure (symptom resolution at the end of therapy),
2. Global cure (clinical cure without recurrence),
3. Time to recurrence,
4. Safety and adverse event reporting,
5. Patient-reported outcomes, including quality-of-life metrics,
6. Healthcare resource utilization and cost-related measures.

In addition to clinical outcomes, the study includes a comprehensive biosample collection strategy for mechanistic and exploratory analyses. Longitudinal sampling of stool, blood, urine, and saliva will allow for in-depth evaluation of:

• Microbiome composition and dynamics,
• Inflammatory and immunological markers,
• Metabolomic profiling,
• Host genetic and genomic predictors of response or recurrence.

These exploratory analyses are intended to improve understanding of host-microbiota interactions in CDI and identify potential biomarkers for personalized treatment approaches.

The sample size of 424 has been statistically powered to detect an absolute difference of at least 15 percentage points in recurrence rates between the FMT group and standard vancomycin, with 80% power and a two-sided significance level of 0.05. This allows for subgroup analyses stratified by age, comorbidities, severity of CDI, and baseline risk factors.

Although the study is open-label, outcome assessment procedures include blinded adjudication by an independent clinical review board to minimize bias. In addition, centralized data monitoring and periodic safety reviews will be conducted to ensure compliance with ethical standards and protocol fidelity.

The STOP-CDI experiment is designed not only to assess comparative efficacy but also to explore real-world feasibility, implementation barriers, and economic considerations associated with newer CDI treatments. It aims to provide decision-makers and clinicians with relevant, actionable evidence that reflects the constraints and opportunities present in everyday clinical practice-particularly in healthcare systems with limited access to novel therapies like fidaxomicin or bezlotoxumab.

Ultimately, the results of this research are expected to guide more personalized, effective, and practical strategies for managing CDI, reducing the burden of recurrence, and improving patient outcomes in diverse clinical and economic contexts.

Enrollment: 424 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals aged 65 years or older OR individuals aged 18 to 64 years who meet at least one of the following criteria:
• Presence of at least two comorbid chronic diseases from the groups of cardiovascular diseases, respiratory system diseases, gastrointestinal diseases, autoimmune diseases, cancers, chronic kidney and genitourinary diseases, immunodeficiencies, diabetes, and metabolic diseases,
• Previous episodes of CDI,
• Healthcare-associated CDI and/or hospitalization within the last three months,
• Concurrent use of antibiotics other than CDI treatment after CDI diagnosis,
• Use of proton pump inhibitors (PPIs) started during or after CDI diagnosis.
• Documented Clostridioides difficile infection, defined according to ESCMID as:

Diagnosis of diarrhea associated with C. difficile defined by:

• > 3 unformed stools (or >200 ml of unformed stool in patients with stool collection devices) within 24 hours before randomization AND
• Clinical signs consistent with CDI and microbiological evidence of free C. difficile toxins in an enzyme immunoassay (EIA) without justified evidence of another cause of diarrhea OR
• Clinical picture consistent with CDI and positive nucleic acid amplification test (NAAT; PCR) preferably with low cycle threshold (Ct) value, or positive toxigenic C. difficile culture OR
• Pseudomembranous colitis diagnosed during endoscopy or colectomy combined with a positive test for toxigenic C. difficile.
• No more than 24 hours of prior treatment with vancomycin, metronidazole, or fidaxomicin.
• Absolute neutrophil count in peripheral blood within 3 days before intervention > 500/µl.
• Ability to swallow large capsules (using test capsules) or no contraindications for FMT via nasojejunal tube, gastroscopy, colonoscopy, or rectal enema.
• Provided informed consent for participation in the clinical study.

Exclusion criteria

• Lack of consent to participate in the study or absence of logical contact without possibility of obtaining consent from an authorized person,
• More than 24 hours of prior treatment with vancomycin, metronidazole, or fidaxomicin,
• On the day of inclusion (up to 3 days before starting intervention) absolute neutrophil count in blood <500 cells/µl or expected drop to this level within the next 2 days,
• Diagnosed HIV infection with CD4 lymphocyte count <250 cells/µl,
• Inability to swallow large capsules (failed test capsule use) or contraindications for FMT via upper or lower gastrointestinal tract, including gastrointestinal perforation, anal atresia, discontinuity of the gastrointestinal tract, and others,
• Known presence of other pathogens in stool known to cause diarrhea,
• Life expectancy <3 months,
• Life-threatening CDI (fulminant at diagnosis - especially with septic shock),
• Total or subtotal colectomy, ileostomy, or colostomy,
• Unwillingness or inability to comply with protocol requirements, including any condition (physical, mental, or social) that may affect the participant's ability to adhere to the protocol.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

424 participants in 3 patient groups

FECAL MICROBIOTA TRANSPLANTATION (with vancomycin short pretreatment phase)

Experimental group

Description:

Participants receive oral vancomycin (125 mg QID) for 5 days (extendable to 10 if needed), followed by FMT. On Day 6, bowel cleansing is performed (macrogol-based), and biological samples (stool, blood, urine, saliva) are collected. On Day 7, FMT is administered via preferred oral capsules or, if necessary, colonoscopy, gastroscopy, NJ tube, or rectal enema. A second FMT is given either as daily capsules on Days 9-14 or as a single dose via other routes on Day 14. Dosing: 6 jars of capsules or 200 mL suspension (≥35 kg); half for \<35 kg. Supportive measures include antiemetics and fasting. Oral non-antibiotic medications continue. Post-FMT samples are collected for follow-up analyses.

Treatment:

Other: FMT (fecal microbiota transplantation)

ANTIBIOTICS ONLY - FIDAXOMICIN

Experimental group

Description:

Participants receive fidaxomicin 200 mg twice daily for 10 days. Biological samples (stool, blood, urine, saliva) are collected at baseline (before first antibiotic dose) for microbiome and safety analyses (PRE ATB). No additional interventions are applied. The antibiotic eradication phase ends on Day 10, after which the participant enters the follow-up phase. Post-treatment biological samples are collected (POST ATB) to assess treatment response, recurrence risk, and microbiota changes.

Treatment:

Drug: Fidaxomicin

ANTIBIOTICS ONLY - VANCOMYCIN

Experimental group

Description:

Participants receive vancomycin 125 mg four times daily for 10 days. Biological samples (stool, blood, urine, saliva) are collected prior to the first dose (PRE ATB) for safety and exploratory analyses. No additional therapies are administered. The eradication procedure is completed on Day 10, followed by a post-treatment sampling phase (POST ATB) for assessment of recurrence, clinical response, and microbiome status.

Treatment:

Drug: Vancomycin (VAN) treatment